CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of head and neck cancer.
  
  LEARNING OBJECTIVES

  • Consider clinical and biologic factors and emerging research information to personalize therapy with novel immunotherapeutic and targeted regimens for patients with head and neck cancer.
  • Appreciate available Phase III findings supporting the FDA approval of pembrolizumab as first-line therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), in combination with platinum-based chemotherapy or as monotherapy for those with PD-L1-positive tumors, and consider the implications of this information for clinical practice.
  • Recall the biologic rationale for dual immune checkpoint inhibitor therapy or for combining immune checkpoint inhibitors with other therapies in the multimodality management of SCCHN, and evaluate ongoing research investigating the potential benefit of these combinations in the locally advanced, recurrent or metastatic disease settings.
  • Consider the clinical relevance of NTRK gene fusions for patients with head and neck cancers, and appreciate available clinical research evidence with and FDA endorsements of larotrectinib and entrectinib for patients with NTRK fusions in order to appropriately select therapy.
  • Design an optimal approach to the clinical care of patients with localized, locally advanced, recurrent or metastatic SCCHN, considering the implications of symptomatology, targetable genetic mutations and other factors.
  • Appraise Phase III data with toripalimab in combination with gemcitabine/cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma, and consider the potential clinical role of this novel agent.
  • Design and implement a plan of care to recognize and manage immune-related adverse events associated with recently approved and emerging immune checkpoint inhibitor regimens and the side effects of other novel targeted regimens to support quality of life and continuation of therapy.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for SCCHN, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Barbara Burtness, MD
  Professor of Medicine
  Yale School of Medicine
  Co-Leader, Developmental Therapeutics Program
  Director, Yale Head and Neck SPORE
  Yale Cancer Center
  New Haven, Connecticut
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Chinook Therapeutics, Cue Biopharma, Debiopharm Group, IO Biotech, Ipsen Biopharmaceuticals Inc, Kura Oncology, MacroGenics Inc, Merck, Nanobiotix, Nuvelution Pharma Inc, Rakuten Medical Inc; Consulting Agreements (Grant/Research/Clinical Trial Support): Bristol-Myers Squibb Company, Cue Biopharma, Merck.
  
  Ezra Cohen, MD
  Professor of Medicine
  Chief, Division of Hematology-Oncology
  Associate Director, Clinical Science
  Moores Cancer Center at UC San Diego Health
  La Jolla, California
  
  Board of Directors: PsiOxus; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Eisai Inc, Gilead Sciences Inc, Janssen Biotech Inc, Kinnate Biopharma, Merck, Merck Sharp & Dohme Corp, Mirati Therapeutics, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc; Ownership Interest: Shares held in Kinnate Biopharma and Primmune Therapeutics.
  
  Robert L Ferris, MD, PhD
  Director, UPMC Hillman Cancer Center
  Hillman Professor of Oncology
  Associate Vice Chancellor for Cancer Research
  Co-Director, Tumor Microenvironment Center
  Professor, Departments of Otolaryngology, Immunology, and Radiation Oncology
  Pittsburgh, Pennsylvania
  
  Advisory Committee: Bristol-Myers Squibb Company, EMD Serono Inc, Instil Bio Inc, Lifescience Dynamics Ltd, MacroGenics Inc, Merck, Numab, Oncocyte, Pfizer Inc, Rakuten Medical; Consulting Agreements: Bicara Therapeutics, Chinook Therapeutics, F Hoffmann-La Roche Ltd, Genocea, Kowa Research Institute Inc, Mirati Therapeutics, Novasenta, Sanofi Genzyme, Zymeworks; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Novasenta, Tesaro, A GSK Company; Stock: Novasenta.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by an educational grant from Merck.
  
  Release date: September 2021
  Expiration date: September 2022